Metabolomics and in-silico analysis reveal critical energy deregulations in animal models of Parkinson's disease
- PMID: 23935941
- PMCID: PMC3720533
- DOI: 10.1371/journal.pone.0069146
Metabolomics and in-silico analysis reveal critical energy deregulations in animal models of Parkinson's disease
Erratum in
- PLoS One. 2014;9(10):e112009
Abstract
Parkinson's disease (PD) is a multifactorial disease known to result from a variety of factors. Although age is the principal risk factor, other etiological mechanisms have been identified, including gene mutations and exposure to toxins. Deregulation of energy metabolism, mostly through the loss of complex I efficiency, is involved in disease progression in both the genetic and sporadic forms of the disease. In this study, we investigated energy deregulation in the cerebral tissue of animal models (genetic and toxin induced) of PD using an approach that combines metabolomics and mathematical modelling. In a first step, quantitative measurements of energy-related metabolites in mouse brain slices revealed most affected pathways. A genetic model of PD, the Park2 knockout, was compared to the effect of CCCP, a mitochondrial uncoupler [corrected]. Model simulated and experimental results revealed a significant and sustained decrease in ATP after CCCP exposure, but not in the genetic mice model. In support to data analysis, a mathematical model of the relevant metabolic pathways was developed and calibrated onto experimental data. In this work, we show that a short-term stress response in nucleotide scavenging is most probably induced by the toxin exposure. In turn, the robustness of energy-related pathways in the model explains how genetic perturbations, at least in young animals, are not sufficient to induce significant changes at the metabolite level.
Conflict of interest statement
Figures
References
-
- Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nature Reviews Neuroscience 2: 492–501. - PubMed
-
- Uversky VN (2007) Neuropathology, biochemistry, and biophysics of α-synuclein aggregation. Journal of Neurochemistry 103: 17–37. - PubMed
-
- Rinne J, Rummukainen J, Paljarvi L, Rinne U (1989) Dementia in Parkinson’s disease is related to neuronal loss in themedial substantia nigra. Annals of Neurology 26: 47–50. - PubMed
-
- Bergareche A, Puente E, López de Munain A, Sarasqueta C, Arce A, et al. (2004) Prevalence of Parkinson’s disease and other types of Parkinsonism. Journal of Neurology 251: 340–345. - PubMed
-
- Halbach OvBu, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson’s disease. Progress in Neurobiology 73: 151–177. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
